Autoantibody tests are everywhere, but how do we make sense of them? With the proper algorithms, can we go beyond interpretation to predicting autoimmunity before it develops? Check out my article: Taking the AI out of AutoImmunity https://t.co/d3ZNYWQaaQ @RheumNow #ACR24

• Taking AI Out of AutoImmunity: Predicting disease before it develops | RheumNow

Risk stratification of GCA pts: who might lose vision? Cranial MRI with vessel wall enhancement used to calculate additive score... # of vessels affected Higher scores a/w ocular GCA > non-ocular GCA > no GCA and decreased w/ tx @RheumNow #ACRbest #ACR24 https://t.co/knDVrl84Qs

• https://x.com/Dr_Brian_MD/status/1858673873157328949/photo/1
• https://x.com/Dr_Brian_MD/status/1858673873157328949/photo/1

Conversation with @RheumKay on his #ACR24 biosimilar talk for @RheumNow https://t.co/LzAIGIG4wu https://t.co/CqSYLpJYAh

• What's The State of Biosimilars?
• https://twitter.com/ericdeinmd/status/1858547083017363622

@drceowen @TheLancetRheum @RheumNow Efficacy in newly diagnosed & established PMR is not necessarily interchangeable different treatment paradigm ?different immunologically Many other diseases have different Rx for induction vs maintenance, early dx vs established. Having said that: doesn't look great for MTX. https://t.co/89lByaYdYq

• https://x.com/drdavidliew/status/1858693549333901326/photo/1

Lot said about #ACR24 ABST1697: MTX in newly diagnosed PMR, neg RCT Many have said no hope for MTX in PMR now Agree doesn't bode well However, MTX may still have role in established PMR @drceowen & I have made that call a priori @TheLancetRheum https://t.co/ywCJc0zHzC @RheumNow https://t.co/JUXk2tDNyR

• Designing studies in newly diagnosed versus established polymyalgia rheumatica
• https://x.com/drdavidliew/status/1858690973573988624/photo/1

#Artificial #Intelligence can detect #osteoporosis On #CXR To detect #thoracic #vertebral #fractures > 100000 #chest #radiographs - test and validation cohorts found + results on ROC Helpful -sometimes vertebral changes are Not read on CXRs #ACR24 @RheumNow @ACRheum #2116 https://t.co/NxEaH0AKJv

• https://x.com/Janetbirdope/status/1858696329712615927/photo/1
• https://x.com/Janetbirdope/status/1858696329712615927/photo/1

#Publication #bias to Nth degree. >1/3 of registered #postmeno #osteoporosis trials are NOT #published 👇search of trials 673 published Vs 489 not published 890000 pts MOSTLY when performed in the USA No accountability for NOT publishing #ACRbest #ACR24 @RheumNow #2122 https://t.co/UyMMbHhvvV

• https://x.com/Janetbirdope/status/1858700516793946146/photo/1

If your pt with #rheumatoid #arthritis is #exhausted - there is a reason #Meta-analysis of 70000 RA Pts #Insomnia is ⬆️4X vs gen population Due to ▶️#pain ▶️#inflammation ▶️#depression 🤷‍♀️ #ACR24 @RheumNow @ACRheum abst#0480

It is NO LONGER a ACCEPTABLE To NOT consider #MMF or #Cyclo + another proven #Rx Added to #HCQ and #tapering /limiting #glucocorticoids RCTs in #lupus #nephritis support this ? Is which to add #belimumab #CNI #volclosporin #obinutuzimab #ACR #ACRbest @RheumNow @ACRheum https://t.co/a7WMFfCyXl

• https://twitter.com/mithurheum/status/1858531398711202080

RheumNow’s expanded coverage of #ACR24 is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty

Paraoxonase-1: Possible Biomarker for Progression to RA Dr. Jonathan Kay discusses abstract 0464, Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population,… https://t.co/yhcCrrvjxH https://t.co/caf5dUvrOQ

JAK-pot! How fast do DMARDs work? Dr. Mike Putman interviews Dr. Kim Lauper about abstract 0501, How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients… https://t.co/GO9EwyrVpV https://t.co/lELE5SJW5i

PREDICT-SpA: Evaluating the influence of gender on disease assessment tools Dr. Sheila Reyes reports on abstract 0571, Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study, presented at #ACR24.… https://t.co/EGlCap6pEw

@DrLisaCS distills the challenges of MCTD 👇 🔵Clinical phenotyping key to improve patient outcomes @jhrheumatology @RheumNow #acr24 https://t.co/APfXPwxvfE

• What is MCTD? The Great Debate